Clinical outcomes of abluminal biodegradable biolimus-eluting stents compared with everolimus-eluting stents in the treatment of the subjects with coronary bifurcation lesions.

Trial Profile

Clinical outcomes of abluminal biodegradable biolimus-eluting stents compared with everolimus-eluting stents in the treatment of the subjects with coronary bifurcation lesions.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Umirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top